Gilead Sciences, Inc. (GILD) Shares Bought by Meyer Handelman Co.
Meyer Handelman Co. increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.7% during the second quarter, Holdings Channel reports. The fund owned 387,500 shares of the biopharmaceutical company’s stock after buying an additional 6,600 shares during the period. Meyer Handelman Co.’s holdings in Gilead Sciences were worth $27,426,000 as of its most recent filing with the SEC.
Several other large investors also recently modified their holdings of GILD. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Gilead Sciences by 1.4% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 101,719 shares of the biopharmaceutical company’s stock valued at $7,199,000 after buying an additional 1,380 shares during the last quarter. US Bancorp DE raised its stake in shares of Gilead Sciences by 16.5% in the second quarter. US Bancorp DE now owns 1,022,039 shares of the biopharmaceutical company’s stock valued at $72,340,000 after buying an additional 144,403 shares during the last quarter. Harvey Capital Management Inc. raised its stake in shares of Gilead Sciences by 0.3% in the second quarter. Harvey Capital Management Inc. now owns 116,260 shares of the biopharmaceutical company’s stock valued at $8,228,000 after buying an additional 300 shares during the last quarter. Bennicas & Associates Inc. raised its stake in shares of Gilead Sciences by 0.4% in the second quarter. Bennicas & Associates Inc. now owns 22,600 shares of the biopharmaceutical company’s stock valued at $1,600,000 after buying an additional 100 shares during the last quarter. Finally, BTIM Corp. bought a new stake in shares of Gilead Sciences during the second quarter valued at about $240,000. Institutional investors own 74.06% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down 0.87% during trading on Friday, reaching $72.07. 3,666,211 shares of the company were exchanged. The stock’s 50 day moving average is $72.31 and its 200 day moving average is $68.76. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $82.10. The company has a market capitalization of $94.12 billion, a price-to-earnings ratio of 7.83 and a beta of 1.21.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. During the same quarter last year, the business earned $3.08 earnings per share. Gilead Sciences’s quarterly revenue was down 8.2% compared to the same quarter last year. Equities analysts anticipate that Gilead Sciences, Inc. will post $8.76 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.86%. Gilead Sciences’s dividend payout ratio (DPR) is currently 22.58%.
TRADEMARK VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Shares Bought by Meyer Handelman Co.” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/gilead-sciences-inc-gild-shares-bought-by-meyer-handelman-co/1472801.html.
Several equities research analysts have recently issued reports on the stock. BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 price target for the company in a research note on Friday, July 28th. Cowen and Company restated an “outperform” rating and set a $90.00 price target on shares of Gilead Sciences in a research note on Thursday, July 27th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $81.00 price objective (up from $79.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $82.00 price objective (up from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Twelve equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $80.31.
In other news, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the sale, the executive vice president now owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at approximately $227,197,799. The disclosure for this sale can be found here. Insiders have sold 206,666 shares of company stock valued at $15,223,184 in the last quarter. 1.30% of the stock is owned by company insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.